January 2019
    Vol 8 Issue 1
From the Editor  
Happy New Year! I'm going to sound like Oprah Winfrey for a moment when I say, "One thing I know for sure": the cancer surveillance world is always changing. With new updates to our staging systems, to new data items for radiation and grade, and all the other new data items, not to mention new treatments - our world is constantly getting updated. But this is actually a good thing. These changes are made with improved patient outcomes in mind and for that we are grateful. Learning about all the changes and keeping on top of them is something else, but it keeps us forever growing and improving ourselves in pursuit of something better for everyone. We continue to bring forward new information and training resources as they become available as noted below.

We start this issue with an article on second melanomas from  Eric Stewart, CRGC Research Associate, with contributions from Dr. Rosemary Cress and Dr. Amy Klepke. I think you'll find the results interesting and agree with the authors' assessment of how they can be utilized in the clinical setting.

Winny Roshala, Director of Data Quality Control and Reporting Facility Compliance Officer for CRGC, provides an article of hematopoietic reportable entities and ones that are no longer reportable as a helpful reminder to all. This is another example of looking at our data and providing useful information to improve our cancer reporting.

We again provide a specific link to the CRGC website where you can find information regarding the changes coming in 2018. Currently posted are several webinars hosted by NAACCR on 2018 Implementation. We will continue to post relevant webinars and resource information to keep you informed. Please remember to wait until the CCR notifies all registrars when 2018 cases can be transmitted. And last but not least, there is a link to the Final version of the SEER Program Manual now available on the NCI SEER website.

Monday, February 4th is World Cancer Day - visit the CRGC's website to see more about this.

We hope you find these articles interesting and informative. CRGC staff thank each of you for your continued support and dedication to providing data of the highest quality! 

Quantifying the risk of second primary melanoma in California, 2000-2015

Eric Stewart, Research Associate, CRGC
Rosemary D. Cress, DrPH,  Research Director, CRGC
Amy Klapheke, MPH, PhD, Research Associate, CRGC

Since transitioning to the Research Unit, I have been exploring the risk of being diagnosed with a second primary melanoma. As many in the data collection realm know, it seems quite common to come across a patient with multiple diagnoses of melanoma. My inspiration for conducting this research came from a conversation I had with a dermatologist while doing data collection. This doctor expressed a need for material to give her patients regarding their continued risk of melanoma after their initial diagnosis. She was having issues getting her patients to return for skin examinations after being diagnosed and wanted something that explained the patient's increased risk of subsequent melanomas in the hope that they would return for examinations every 3 to 6 months (the current standard set by the American Academy of Dermatology). In addition to quantifying risk in the population, a main goal of this research was to create a pamphlet that could be used by dermatologists to help them educate patients in their daily practice.

Data Quality Reminders
Winny Roshala, BA, CTR
Director , Data Quality Control and Reporting Facility Compliance Officer 
Acknowledgement to Taina Valone, RHIA, CTR, for identifying these data quality issues.

Reminder: The following Hematopoietic Diseases below became reportable in 1/1/2001. If a case with any of the diagnoses below is encountered at your facility, but originally diagnosed prior to 1/1/2001, the case is not reportable. We have been seeing a few of these entities being reported recently. These cases are identified and deleted in the Eureka database.

Historic Volume I, Section II.1.8 Newly Reportable Hematopoietic Diseases (NRHD) 

For 1/1/2001 to 1/1/2010

Newly Reportable Hematopoietic Diseases (NRHD) are defined as any of the myeloproliferative or myelodysplastic diseases that changed behavior from /1 borderline to /3 malignant in ICD-O-3.
Abstract and report only NRHD cases diagnosed 1/1/2001 forward.
If disease is known prior to 2001, do not report the case. NRHD cases diagnosed prior to 1/1/2001 undergoing active treatment at your facility are not reportable cases.

SEER Program Manual - Final Version Posted

The Draft version of the 2018 SEER Program Manual has been replaced with the Final version. There are two change logs available: one for the changes between the 2016 manual and the draft 2018 manual, and another for the changes between the draft 2018 manual and the final 2018 manual.

Please visit the SEER Program Manual page of the SEER website,
If you need to refer to the draft version, it is located under Historical Coding and Staging Manuals,
2018 Data Implementation Posted on CRGC Website

CRGC has created a special location on our website regarding 2018 Implementation and Data Changes to help keep our registrar community informed. Currently posted are four webinars, hosted by NAACCR, that we found especially helpful.

We will continue to post resources and other webinars on 2018 Data Changes to this site as they become available. We hope that having one spot to look for information regarding the changes coming in 2018 will prove helpful to each of you. It is under CRGC Website/Registrar Resources/Registrar Education.

Cancer Registrar Feedback
If you have questions, comments, or suggestions for Chats contact Mignon Dryden at
PHI logo
Cancer Registry of Greater California
Public Health Institute
1825 Bell Street, Suite 102
Sacramento, California 95825